Fig. 3
CD40-TRAF6 inhibition alleviated CAV in bm12 to C57BL/6 cardiac transplantation models. (A,B) The murine cardiac heart transplantation model was performed using BM12 mice as donors and C57BL/6 as recipients. CD40-TRAF6 specific antagonist or DMSO was administered after transplantation (n = 5 for each group). (C) HE staining of cardiac allografts from recipient mice 60 days after heart transplantation. (D) Masson staining of cardiac allografts from recipient mice 60 days after heart transplantation. (E) Immunofluorescence assay of cardiac allografts infiltrated by CD4 + cells. (F,G) FCM assays of CD4 + IFN-γ + splenocytes(p = 0.001) and CD4 + IL-2 + splenocytes(p = 0.017). (H,I) FCM assays of F4/80 + CD80 + cells and F4/80 + CD206 + splenocytes. (J) Immunofluorescence assay of cardiac allografts infiltrated by CD11b + cells. (K,L) Immunohistochemical assay of cardiac allografts infiltrated by CD11b + cells, i-NOS + , and Arg-1cells.
